List of Excipients in Branded Drug NASCOBAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ENDO USA Inc	NASCOBAL	cyanocobalamin	49884-270	BENZALKONIUM CHLORIDE
ENDO USA Inc	NASCOBAL	cyanocobalamin	49884-270	CITRIC ACID MONOHYDRATE
ENDO USA Inc	NASCOBAL	cyanocobalamin	49884-270	GLYCERIN

Nascobal Excipient Strategy and Commercial Opportunities for Cyanocobalamin Nasal Spray

Last updated: August 13, 2026

Nascobal is a prescription cyanocobalamin nasal spray containing 500 mcg of vitamin B12 per 0.1 mL spray. Its excipient system is conventional for an aqueous nasal product: benzalkonium chloride, citric acid, sodium citrate, glycerin, and purified water. The main commercial opportunities are a preservative-free multidose product, a unit-dose nasal presentation, improved spray-device performance, and formulations designed for better tolerability or higher mucosal residence time.

The largest strategic constraint is that oral and injectable vitamin B12 products are widely available and inexpensive. A new nasal product therefore needs a clear advantage in adherence, tolerability, convenience, or use in patients who cannot reliably use oral or intramuscular therapy.

What is Nascobal and which excipients does it contain?

Nascobal is an intranasal formulation of cyanocobalamin used for vitamin B12 replacement, including treatment of pernicious anemia after initial correction and maintenance therapy. The marketed product delivers 500 mcg of cyanocobalamin in 0.1 mL per spray.[1]

Nascobal composition

Component	Function in the formulation
Cyanocobalamin	Active pharmaceutical ingredient
Benzalkonium chloride	Antimicrobial preservative
Citric acid	pH adjustment and buffering
Sodium citrate	Buffer component
Glycerin	Humectant and tonicity modifier
Purified water	Aqueous vehicle

The formulation is an aqueous buffered nasal spray. Glycerin can improve product feel and reduce irritation associated with a low-solids aqueous formulation. The citrate system maintains the formulation within a pH range compatible with cyanocobalamin stability and nasal administration.

Benzalkonium chloride is the most commercially significant excipient in the existing product. It supports multidose microbial control but is associated with potential nasal irritation and, with repeated exposure, concerns about effects on the nasal mucosa. A reformulation that removes benzalkonium chloride could provide a meaningful product-differentiation platform.

What formulation patents protect Nascobal?

Public FDA labeling identifies the composition and dosage form but does not establish a current, commercially meaningful patent barrier for the excipient system. The principal formulation components are well-known pharmaceutical excipients, and the product has been marketed for decades. A new entrant should assume that broad claims covering cyanocobalamin in an aqueous nasal spray would face validity and obviousness challenges unless supported by specific performance data.

Patentability of a Nascobal reformulation

Potentially protectable subject matter includes:

• A preservative-free multidose formulation with demonstrated microbial robustness.
• A specific pH and buffer concentration that improves cyanocobalamin stability.
• A formulation with reduced nasal irritation.
• A spray-device and formulation combination that produces a defined droplet-size distribution.
• A unit-dose package that limits microbial contamination without a preservative.
• A mucoadhesive formulation that increases nasal residence time or absorption.
• A formulation with improved chemical stability under light, heat, or oxygen stress.
• A specific combination of cyanocobalamin concentration, viscosity, surface tension, and pump characteristics.

The strongest patent position would ordinarily require comparative data against the marketed Nascobal formulation. Useful evidence would include delivered-dose uniformity, plume geometry, droplet-size distribution, assay, degradation products, preservative effectiveness, microbial limits, nasal tolerability, and pharmacokinetic exposure.

A claim limited to the presence of glycerin, citrate, or benzalkonium chloride would likely provide weak exclusionary value because those excipients are standard formulation tools. Claims tied to a measurable technical effect are more commercially defensible.

When does Nascobal lose exclusivity?

Nascobal’s original regulatory exclusivity and any early composition or formulation patents are not the primary current barrier to competition. The product’s commercial protection is more likely to depend on regulatory complexity, limited market size, device development, manufacturing know-how, and the absence of an established generic nasal spray.

Exclusivity and patent considerations

Protection category	Strategic relevance
Original NDA exclusivity	Expected to have expired
Original formulation patents	Any early patents would generally be expected to have expired or lost practical significance
Orange Book patents	Must be checked against the current FDA Orange Book before filing strategy is finalized
New formulation patents	Could create protection for a differentiated product
Device patents	May protect pump architecture, dose metering, or packaging
Trade secrets	Can protect process controls, filling, stability programs, and device assembly
Regulatory exclusivity for a new product	Could arise from a qualifying new clinical or formulation program, but is not automatic

The commercial question is therefore less about extending an old Nascobal patent and more about creating a new, clinically relevant product profile.

What is the Orange Book status of Nascobal?

Nascobal is associated with an FDA-approved prescription drug product containing cyanocobalamin for nasal administration. FDA Orange Book treatment depends on the reference product designation, current marketing status, and any listed patents or exclusivity entries.[2]

For an ANDA strategy, a sponsor would need to establish that its product has the same active ingredient, dosage form, route of administration, strength, and relevant pharmaceutical characteristics as the reference listed drug. If the proposed product changes the preservative, device, formulation, or dosage presentation in a way that prevents a straightforward sameness showing, a 505(b)(2) application may be more appropriate.

ANDA versus 505(b)(2) strategy

Development route	Best use case	Key burden
ANDA	Same formulation, same strength, same nasal spray characteristics, and equivalent performance	Pharmaceutical equivalence, bioequivalence, device and quality bridging
505(b)(2) NDA	Preservative-free product, new device, altered excipient system, new dosing schedule, or new clinical positioning	Reliance on prior findings plus additional nonclinical, clinical, or comparative data
New NDA	Materially new delivery platform or clinical use	Full development program

A preservative-free unit-dose product could potentially fit an ANDA pathway if the product remains pharmaceutically equivalent and the device does not create a material difference. A preservative-free multidose product with a new container-closure system and a novel antimicrobial-control strategy would more likely require a 505(b)(2) assessment.

What excipient strategies could improve Nascobal?

1. Remove benzalkonium chloride

The most direct opportunity is to develop a preservative-free product. The product could use:

• Unit-dose ampoules or single-use nasal applicators.
• A sterile blow-fill-seal container.
• A pump with an antimicrobial container-closure system.
• A formulation packaged in a device that prevents backflow and microbial ingress.
• A low-volume presentation intended for a defined treatment period.

The commercial benefit would be a cleaner tolerability profile and a potential advantage for chronic maintenance therapy. The development burden would include container-closure integrity, sterility or microbial-control validation, in-use stability, extractables and leachables, and delivered-dose testing.

2. Optimize pH and buffering

Cyanocobalamin stability can be affected by light, oxygen, temperature, and formulation conditions. A revised citrate buffer system could seek to improve shelf life or reduce nasal discomfort.

A useful development program would screen:

• pH around the existing product range and adjacent values.
• Citrate concentration.
• Ionic strength.
• Oxygen exposure.
• Light protection.
• Antioxidant compatibility, if justified.
• Interaction with the nasal pump and primary container.

The key limitation is that pH changes can affect both stability and nasal tolerability. A formulation that is chemically more stable but causes burning or congestion would have limited commercial value.

3. Rebalance glycerin and tonicity

Glycerin contributes to humectancy, viscosity, and sensory properties. Its concentration can affect:

• Nasal burning or dryness.
• Spray plume and droplet size.
• Residence time.
• Dose recovery from the pump.
• Patient perception of dripping or run-off.

A lower-glycerin formulation may improve spray feel, while a higher-viscosity formulation may increase retention but create inconsistent dosing or a less acceptable plume. The optimal strategy is device-specific and must be tested with the final commercial pump.

4. Introduce a mucoadhesive system

Mucoadhesive excipients could increase nasal residence time and reduce posterior drainage. Candidate classes include certain cellulose derivatives, polyacrylates, chitosan derivatives, and other approved or pharmaceutically characterized polymers.

The opportunity is technically attractive but carries substantial risk. A mucoadhesive formulation must demonstrate:

• Consistent delivered dose.
• Acceptable sprayability.
• No excessive viscosity.
• No unacceptable nasal irritation.
• No adverse effect on mucociliary clearance.
• Stable cyanocobalamin content.
• Reliable absorption or exposure.

Mucoadhesion alone would not establish clinical superiority. The product would need evidence that increased residence time improves pharmacokinetics, dose consistency, adherence, or patient outcomes.

What commercial opportunities exist for a Nascobal reformulation?

Preservative-free maintenance therapy

The clearest opportunity is a preservative-free product for patients requiring long-term vitamin B12 maintenance. The commercial message would focus on tolerability, reduced exposure to benzalkonium chloride, and simplified chronic use.

This opportunity is stronger if the product has:

• A simple once-weekly or physician-directed administration schedule.
• A compact device.
• A defined number of doses per package.
• Stable room-temperature storage.
• Low priming waste.
• Dose counters or feedback mechanisms.

Unit-dose nasal B12

Unit-dose packaging could address microbial-control concerns and simplify regulatory justification for a preservative-free product. The main disadvantages are higher packaging costs, more waste, and potentially lower convenience for long-term users.

A unit-dose product may be commercially attractive in:

• Specialty pharmacy.
• Home healthcare.
• Assisted living.
• Patients with dexterity limitations.
• Clinics administering replacement therapy.
• Travel or adherence-oriented packaging.

Improved nasal tolerability

A formulation with lower irritation could compete against the perception that injectable therapy is more reliable and oral therapy is cheaper. The product would need comparative tolerability data rather than relying only on excipient changes.

Relevant endpoints could include:

• Burning and stinging scores.
• Nasal congestion.
• Rhinorrhea.
• Epistaxis.
• Discontinuation rates.
• Patient preference.
• Use over several months.

Adherence-focused delivery

Nasal administration offers a noninvasive alternative to intramuscular injection. A commercial product could differentiate through packaging and adherence tools rather than through a new excipient alone.

Potential features include:

• Dose counters.
• Electronic reminders.
• Calendar blister packaging for ancillary supplies.
• Pharmacy refill synchronization.
• QR-linked administration instructions.
• Caregiver-oriented packaging.

These features may be protectable through device or software claims, but they are unlikely to support pharmaceutical pricing without evidence of improved persistence or clinical use.

How does Nascobal compare with oral and injectable vitamin B12?

Attribute	Nascobal nasal spray	Oral cyanocobalamin	Intramuscular cyanocobalamin
Administration	Noninvasive nasal dosing	Simple oral dosing	Injection
Main advantage	Avoids swallowing and injections	Lowest cost and broad availability	Established use in severe deficiency
Main limitation	Higher product and device complexity	Adherence and absorption concerns in some patients	Pain, clinic access, and administration burden
Excipient opportunity	High, because spray tolerability and preservation matter	Lower, because tablets and capsules are mature	Limited formulation differentiation
Generic pressure	Potentially limited by device and nasal equivalence	High	High
Commercial differentiation	Preservative-free, tolerability, adherence, device	Convenience and low price	Reliability and clinical familiarity

Nascobal’s value proposition depends on a specific patient segment. It is unlikely to compete broadly with inexpensive oral B12 on price. Its more defensible position is as a noninjectable option for patients who have difficulty with oral therapy or prefer to avoid injections.

What generic entry risks exist for Nascobal?

Generic entry risk is moderate from a technical perspective but high from a substitution perspective if a company successfully develops an equivalent nasal spray. The active ingredient is inexpensive and well known. The barriers are formulation sameness, nasal-device performance, bioequivalence, manufacturing scale, and market economics.

Likely generic launch scenarios

Scenario	Market effect
Same formulation and comparable pump	Rapid price pressure if FDA approval is obtained
Preservative-free generic	Segment expansion and possible premium positioning
New nasal device with equivalent product	Potential substitution if device usability is superior
Oral B12 price competition	Limits Nascobal pricing power
Injectable supply disruption	Temporary demand shift toward nasal products
Specialty-pharmacy contracting	Could determine access more than formulation advantages

A generic manufacturer may avoid a large clinical program by pursuing an ANDA, but the nasal route can create more complex equivalence questions than a conventional tablet. Device performance, spray pattern, priming, repriming, residual volume, and dose uniformity can affect the filing.

Which companies are positioned to challenge Nascobal?

The most credible challengers are companies with experience in:

• Nasal drug-device combinations.
• Generic prescription products.
• Sterile or microbiologically controlled liquid manufacturing.
• Specialty pharmacy distribution.
• 505(b)(2) product development.
• Vitamin and nutritional products.

A competitor does not need a novel B12 molecule. It needs a reliable formulation, a validated nasal pump, a scalable filling process, and a reimbursement strategy. Contract manufacturers with nasal spray capabilities could reduce development barriers, while generic companies could target an equivalent product if the reference product and regulatory pathway are commercially attractive.

What manufacturing and IP barriers affect Nascobal competition?

The principal manufacturing barriers are practical rather than molecule-specific:

• Cyanocobalamin light sensitivity.
• Control of oxygen and degradation products.
• Accurate low-volume filling.
• Pump-to-pump dose uniformity.
• Container-closure integrity.
• Microbial control in multidose packaging.
• Compatibility between formulation and elastomers or plastics.
• Device priming and storage orientation.
• Stability after first use.
• Consistent spray plume and droplet distribution.

Manufacturing know-how can create a meaningful advantage even where patent protection is limited. A robust process may reduce batch failures and support a longer shelf life. It can also lower the risk of device complaints, which is commercially important for a chronic-use nasal product.

How strong is the Nascobal patent estate?

The legacy patent estate appears commercially weaker than the product’s formulation and device barriers. The active ingredient is an established vitamin, the principal excipients are conventional, and the product has an extended marketing history. Any new competitive protection would need to focus on a specific formulation, device, packaging system, or clinically demonstrated performance advantage.

Patent-strength assessment

Asset	Relative strength
Cyanocobalamin composition	Weak
Conventional citrate-glycerin aqueous formulation	Weak
Benzalkonium chloride preservation system	Weak to moderate, depending on claim scope
Preservative-free multidose system	Moderate if supported by technical data
Unit-dose container and closure	Moderate
Spray-device architecture	Moderate to strong if nonstandard and well claimed
Mucoadhesive formulation	Moderate, subject to enablement and obviousness
Improved tolerability or absorption claim	Stronger if supported by comparative clinical data
Manufacturing process	Potentially valuable as trade secret; patent strength depends on specificity

What FDA regulatory issues apply to a new Nascobal product?

FDA review would focus on the relationship between formulation, device, route of administration, and therapeutic exposure. Key regulatory workstreams include:

1. Product characterization and assay.
2. Impurity and degradation-product control.
3. Preservative effectiveness or preservative-free microbial strategy.
4. Nasal spray performance.
5. Extractables and leachables.
6. Stability in the final container.
7. Local nasal tolerability.
8. Pharmacokinetic comparability.
9. Human factors and device usability.
10. Labeling for chronic maintenance use.

A new excipient without prior nasal use may increase the nonclinical and clinical burden. A reformulation using established nasal excipients can reduce, but not eliminate, regulatory risk.

Key Takeaways

• Nascobal contains cyanocobalamin 500 mcg per 0.1 mL and uses benzalkonium chloride, citrate buffer, glycerin, and purified water.[1]
• The most compelling excipient opportunity is a preservative-free nasal product.
• Unit-dose packaging can solve microbial-control problems but increases packaging cost and waste.
• Mucoadhesive and viscosity-modified systems offer differentiation but require strong tolerability and performance data.
• Broad claims on conventional excipients are likely to have limited patent strength.
• Device, container-closure, formulation-performance, and manufacturing claims offer more defensible protection.
• An ANDA may be viable for a genuinely equivalent product; a 505(b)(2) pathway is more likely for material formulation or device changes.
• Oral B12 creates a major pricing constraint, while injectable B12 provides the clearest noninvasive substitution opportunity.
• Commercial success depends on adherence, tolerability, device usability, and reimbursement rather than cyanocobalamin novelty.

FAQs

Can benzalkonium chloride be removed from Nascobal?

Yes. A preservative-free product is technically feasible, but it would require a redesigned container-closure and microbial-control strategy. Unit-dose packaging is the most straightforward approach.

Is glycerin essential in a cyanocobalamin nasal spray?

No. Glycerin is a formulation aid rather than the active ingredient. Its concentration can be optimized, but changes may affect viscosity, nasal feel, spray pattern, and dose delivery.

Could a new Nascobal formulation receive separate patent protection?

Yes, if the formulation or device has novel claim elements and demonstrates a credible technical effect. A simple substitution of one conventional excipient for another would usually provide weaker protection.

Is a cyanocobalamin nasal spray likely to qualify for an ANDA?

It may qualify if the proposed product matches the reference product in the relevant pharmaceutical and device characteristics. A materially different preservative system, pump, dosing regimen, or clinical use may favor a 505(b)(2) application.

What is the strongest commercial positioning for a new nasal B12 product?

The strongest positioning is a preservative-free, easy-to-use, noninjectable maintenance product with demonstrated nasal tolerability and reliable dose delivery. Competing primarily on price against oral cyanocobalamin would be less attractive.

References

1. Food and Drug Administration. (2023). Nascobal cyanocobalamin nasal spray prescribing information.
2. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Food and Drug Administration. (1999). Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation.
4. Food and Drug Administration. (2013). Bioequivalence studies for nasal aerosols and nasal sprays: Guidance for industry.
5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.